$ARRY Announces 15.3 Months Median OS from the Safety Lead-in of the Ph 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer https://www.prnewswire.com/news-releases/array-biopharma-announces-15-3-months-median-overall-survival-from-the-safety-lead-in-of-the-phase-3-beacon-crc-trial-of-the-combination-braftovi-mektovi-and-erbitux-in-braf-mutant-metastatic-colorectal-cancer-300778031.html …